The AIDS Malignancy Consortium (AMC) was established in 1995 to evaluate clinical interventions for the treatment and prevention of malignancies in HIV and to investigate the biology of malignancies in the context of Clinical trials. Since then, the AMC has conducted 31 clinical trials involving 1934 patients with primarily HIV related malignancies, 991 (51%) enrolled since the beginning of the current grant cycle in 2006. Twelve studies are currently enrolling patients or are in late stages of protocol development. Several key scientific findings have emerged from AMC studies that have led to improvements in the treatment or management of patients and has helped establish the current standard of care in some cases. The group has more than doubled the number of its publication in the current cycle compared to its first 10 years. In addition, the AMC has initiated a process to include subjects with HIV-associated cancers in resource poor countries where the epidemic of HIV and cancer has grown substantially. The participation of many of the key clinical and laboratory researchers in AIDS malignancies in the USA has made the AMC the principal clinical trials group in the world dedicated to improving the treatment and prevention of cancers in this population. The scientific work of the group is focused in 4 disease-specific and one laboratory working groups;Kaposi's sarcoma, Lymphoma, Human Papillomavirus, Non-AIDS defining Cancers (NADC), and Laboratory and Translational Sciences Working Groups. In addition 3 resources committees support the work of the group;International, Outreach, Education and Recruitment and Laboratory (which oversees core labs in pharmacology, pathology, virology, biomarkers and developmental therapeutics). An Operations and Data Management Center (ODMC) at The EMMES Corporation, a Statistical Center at the University of Arkansas, and the Group Chair's Office at UCLA also support the AMC. Decision making authority is vested in the Group Chair and the Executive Committee (EC) with the Steering Committee providing scientific input and advice to the EC. The AMC consists of 8 core sites (including 3 combined city units) and 16 affiliated domestic sites. We are also in the process of establishing a network of international sites in resource-poor countries of Africa.

Public Health Relevance

Cancer has been recognized as one of the clinical manifestations of AIDS since the beginning of the epidemic, and despite improvements in mortality with potent antiretrovial therapy, cancer remains a leading cause of morbidity and morbidity in the developed and resource limited areas of the world. The spectrum of these cancers in HIV is quite diverse and many NADC are becoming more widely recognized. The AMC is one of the few organizations worldwide that is dedicated to the study of malignancies in HIV.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA121947-07S1
Application #
8736026
Study Section
Special Emphasis Panel (ZCA1-SRLB-D (O2))
Program Officer
Liddell Huppi, Rebecca
Project Start
2006-08-29
Project End
2015-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
7
Fiscal Year
2013
Total Cost
$5,600,000
Indirect Cost
$10,485
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Barta, Stefan K; Joshi, Jitesh; Mounier, Nicolas et al. (2016) Central nervous system involvement in AIDS-related lymphomas. Br J Haematol 173:857-66
Gopal, Satish; Fedoriw, Yuri; Kaimila, Bongani et al. (2016) CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi. PLoS One 11:e0150445
Alvarnas, Joseph C; Le Rademacher, Jennifer; Wang, Yanli et al. (2016) Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood 128:1050-8
Epeldegui, Marta; Lee, Jeannette Y; Martínez, Anna C et al. (2016) Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). Clin Cancer Res 22:328-36
Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7
Hernandez, Alexandra L; Karthik, Rajiv; Sivasubramanian, Murugesan et al. (2016) Prevalence of Anal HPV Infection Among HIV-Positive Men Who Have Sex With Men in India. J Acquir Immune Defic Syndr 71:437-43
Montgomery, Nathan D; Liomba, N George; Kampani, Coxcilly et al. (2016) Accurate Real-Time Diagnosis of Lymphoproliferative Disorders in Malawi Through Clinicopathologic Teleconferences:  A Model for Pathology Services in Sub-Saharan Africa. Am J Clin Pathol 146:423-30
Willeford, Wesley G; Bachmann, Laura H (2016) Uncertainty Abounds in the World of Anal Dysplasia Screening. Sex Transm Dis 43:436-7
Bender Ignacio, Rachel A; Lee, Jeannette Y; Rudek, Michelle A et al. (2016) Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. J Acquir Immune Defic Syndr 72:52-7
Noy, Ariela; Lensing, Shelly Y; Moore, Page C et al. (2016) Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. Leuk Lymphoma 57:1731-4

Showing the most recent 10 out of 105 publications